Media
Hua Medicine hires AstraZeneca China Diabetes Veteran as VP, Head of Commercial Strategy and Marketing
Shanghai, China – August 9, 2018
Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced Wenjie Xu, an experienced sales & marketing veteran in China, joins Hua Medicine as VP, Head of Commercial Strategy and Marketing.
Ms. Wenjie Xu brings with her over 20 years of experience working in various sales and marketing roles at multi-national pharmaceutical firms in China. Prior to joining Hua, she was the Executive Director of the Cardiovascular, Renal, and Metabolic Business Unit at AstraZeneca China. Ms. Xu’s principal responsibility at AstraZeneca China was sales and marketing of their diabetes franchise in China, including the launch of Forxiga (dapagliflozin) She also served in various sales and marketing roles at Eli Lilly from February 2007 to December 2015, focused on diabetes starting in 2009. Prior to Eli Lilly, Ms. Xu served in sales and marketing functions of various international and domestic pharmaceutical companies, including Amgen China. Ms. Xu received a Bachelor’s degree in Pharmaceutical analysis from the China Pharmaceutical University, and a Master of Business Administration from Goizueta Business School, Emory University.
▲Ms. Wenjie Xu
As Hua's Head of Commercial Strategy & Marketing, Wenjie’s key responsibilities will be to develop the commercial and marketing strategies of the company’s products, manage marketing and product education activities, and the training of sales staff.
Hua Medicine successfully completed its proof-of-concept study Phase II clinical trial for Dorzagliatin (HMS5552), a novel 1st-in-class Glucokinase Positive Allosteric Modulator (PAM) for the treatment of diabetes in 258 patients in 22 leading hospital centers across China in 2016. The Phase II data was published in the Lancet, Diabetes and Endocrinology on May 8, 2018. In China, the company has initiated the NDA enabling process and has started two Phase III clinical trials targeting drug-naive and metformin treated T2D patients in China led by Professor Dalong Zhu, President-elect of China Diabetes Society (CDS), and Professor Wenying Yang, Former President of CDS, with 110 clinical sites located throughout China participating.
"We are very excited to have Wenjie join the Hua team, leading our commercialization and marketing efforts." said Dr. Li Chen, CEO of Hua Medicine. "Wenjie is highly experienced in the sales and marketing of diabetes drugs in the China market. As Hua’s head of commercial strategy and marketing, her experience and network in China’s diabetes market will be critical in helping us deliver Dorzagliatin to the world’s largest diabetes population."
About Hua Medicine
Hua Medicine is a China-based drug development company currently focused on developing a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 Diabetes (T2D). Dorzagliatin is a fourth generation glucokinase activator, originated at Roche AG, and in-licensed by Hua Medicine as a pre-clinical stage compound. Hua Medicine retains global rights to Dorzagliatin. Founded and funded by well-known and highly experienced US and China biotech specialists, including our founder and CEO, Dr. Li Chen (the former Chief Scientific Officer of Roche China).Hua Medicine is comprised of a team with extensive experience in global pharmaceutical research and development, and a portfolio advisory board comprised of some of the industry’s most significant key opinion leaders, academics, and scientists. According to Frost & Sullivan, there were 435 million individuals with T2D in 2017 globally. China has the world’s largest diabetes population, with 120 million individuals in 2017, and 52.8% are currently undiagnosed.
沪ICP备14036654号-1
沪公网安备 31011502013809号
